Aktienanalyse zu Inogen Inc (INGN)INGNInogen Inc

Inogen, Inc. is a global medical technology company offering respiratory products for use in the homecare setting. The Company partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products available. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators (POCs), used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. It also distributes the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure (CPAP) masks in the United States. Its proprietary Inogen One and Inogen Rove POC systems concentrate the air around the patient to offer a source of supplemental oxygen 24 hours a day, seven days a week with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Inogen Inc is currently trading at $5.50, significantly below the analyst target of $12, indicating potential upside. However, the stock has a low RSI of 25.471, suggesting it is oversold, but the recent performance shows a 1-year change of -32.10%, indicating a prolonged downtrend. The company has reaffirmed its revenue outlook for 2026 at $366 million to $373 million, which reflects confidence in future growth despite recent losses.

6 analysts cover INGN: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 13.00.